{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T18:17:55Z","timestamp":1783707475959,"version":"3.55.0"},"publisher-location":"Berlin, Heidelberg","reference-count":148,"publisher":"Springer Berlin Heidelberg","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/164_2026_821","type":"book-chapter","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:48:43Z","timestamp":1783705723000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["TAAR1 as a Potential Alternate Molecular Target to GLP-1 for Novel Anti-diabetic, Anti-obesity Medications"],"prefix":"10.1007","author":[{"given":"Rhianna K.","family":"Lenham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatema","family":"Elgammal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott V.","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"821_CR1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.pbb.2011.10.025","volume":"101","author":"C Achat-Mendes","year":"2012","unstructured":"Achat-Mendes C et al (2012) Augmentation of methamphetamine-induced behaviors in transgenic mice lacking the trace amine-associated receptor 1. Pharmacol Biochem Behav 101:201\u2013207","journal-title":"Pharmacol Biochem Behav"},{"key":"821_CR2","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00406-023-01580-3","volume":"273","author":"ED Achtyes","year":"2023","unstructured":"Achtyes ED et al (2023) Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia. Eur Arch Psychiatry Clin Neurosci 273:1543\u20131556","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"821_CR3","volume":"4","author":"A Acosta","year":"2025","unstructured":"Acosta A et al (2025) Acute pancreatitis and euglycemic non-diabetic ketoacidosis caused by an intentional semaglutide overdose. JEM Reports 4:100139","journal-title":"JEM Reports"},{"key":"821_CR4","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1210\/en.2015-1301","volume":"156","author":"A Adriaenssens","year":"2015","unstructured":"Adriaenssens A et al (2015) A transcriptome-led exploration of molecular mechanisms regulating somatostatin-producing D-cells in the gastric epithelium. Endocrinology 156:3924\u20133936","journal-title":"Endocrinology"},{"key":"821_CR5","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1016\/j.celrep.2016.11.072","volume":"17","author":"J Alma\u00e7a","year":"2016","unstructured":"Alma\u00e7a J et al (2016) Human beta cells produce and release serotonin to inhibit glucagon secretion from alpha cells. Cell Rep 17:3281\u20133291","journal-title":"Cell Rep"},{"key":"821_CR6","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.2337\/db16-0755","volume":"66","author":"RH Anderberg","year":"2017","unstructured":"Anderberg RH et al (2017) Glucagon-like peptide 1 and its analogs act in the dorsal raphe and modulate central serotonin to reduce appetite and body weight. Diabetes 66:1062\u20131073","journal-title":"Diabetes"},{"key":"821_CR7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104642","volume":"93","author":"C Aran\u00e4s","year":"2023","unstructured":"Aran\u00e4s C et al (2023) Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats. EBioMedicine 93:104642","journal-title":"EBioMedicine"},{"key":"821_CR8","doi-asserted-by":"crossref","first-page":"241","DOI":"10.4239\/wjd.v10.i4.241","volume":"10","author":"J Aravinda","year":"2019","unstructured":"Aravinda J (2019) Risk factors in patients with type 2 diabetes in Bengaluru: a retrospective study. World J Diabetes 10:241\u2013248","journal-title":"World J Diabetes"},{"key":"821_CR9000","doi-asserted-by":"crossref","unstructured":"Arillotta D et al (2023) GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach. Brain Sci 13:1503","DOI":"10.3390\/brainsci13111503"},{"key":"821_CR9","volume":"7","author":"S Asad","year":"2012","unstructured":"Asad S et al (2012) HTR1A a novel type 1 diabetes susceptibility gene on chromosome 5p13-q13. PLoS One 7:e35439","journal-title":"PLoS One"},{"key":"821_CR10","doi-asserted-by":"crossref","first-page":"13901","DOI":"10.1038\/s41598-017-14472-z","volume":"7","author":"A Asif-Malik","year":"2017","unstructured":"Asif-Malik A, Hoener MC, Canales JJ (2017) Interaction between the trace amine-associated receptor 1 and the dopamine D2 receptor controls cocaine\u2019s neurochemical actions. Sci Rep 7:13901","journal-title":"Sci Rep"},{"key":"821_CR11","doi-asserted-by":"crossref","first-page":"9317987","DOI":"10.1155\/2018\/9317987","volume":"2018","author":"SB Aynalem","year":"2018","unstructured":"Aynalem SB, Zeleke AJ (2018) Prevalence of diabetes mellitus and its risk factors among individuals aged 15 years and above in Mizan-Aman Town, Southwest Ethiopia, 2016: a cross sectional study. Int J Endocrinol 2018:9317987","journal-title":"Int J Endocrinol"},{"key":"821_CR12","doi-asserted-by":"crossref","first-page":"519","DOI":"10.5483\/BMBRep.2013.46.11.207","volume":"46","author":"JH Baik","year":"2013","unstructured":"Baik JH (2013) Dopamine signaling in food addiction: role of dopamine D2 receptors. BMB Rep 46:519\u2013526","journal-title":"BMB Rep"},{"key":"821_CR13","doi-asserted-by":"crossref","first-page":"11576","DOI":"10.3390\/ijms222111576","volume":"22","author":"DA Barnes","year":"2021","unstructured":"Barnes DA et al (2021) TAAR1 expression in human macrophages and brain tissue: a potential novel facet of MS neuroinflammation. Int J Mol Sci 22:11576","journal-title":"Int J Mol Sci"},{"key":"821_CR14","doi-asserted-by":"crossref","first-page":"e0194127","DOI":"10.1371\/journal.pone.0194127","volume":"13","author":"V Bellou","year":"2018","unstructured":"Bellou V et al (2018) Risk factors for type 2 diabetes mellitus: an exposure-wide umbrella review of meta-analyses. PLoS One 13:e0194127\u2013e0194127","journal-title":"PLoS One"},{"key":"821_CR15","doi-asserted-by":"crossref","first-page":"540718","DOI":"10.3389\/fped.2020.540718","volume":"8","author":"J Beltrand","year":"2020","unstructured":"Beltrand J et al (2020) Neonatal Diabetes Mellitus. Front Pediatr 8:540718\u2013540727","journal-title":"Front Pediatr"},{"key":"821_CR16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.peptides.2015.07.008","volume":"71","author":"H Bennet","year":"2015","unstructured":"Bennet H et al (2015) Altered serotonin (5-HT) 1D and 2A receptor expression may contribute to defective insulin and glucagon secretion in human type 2 diabetes. Peptides 71:113\u2013120","journal-title":"Peptides"},{"key":"821_CR17","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.pharmthera.2017.07.002","volume":"180","author":"MD Berry","year":"2017","unstructured":"Berry MD et al (2017) Pharmacology of human trace amine-associated receptors: therapeutic opportunities and challenges. Pharmacol Ther 180:161\u2013180","journal-title":"Pharmacol Ther"},{"key":"821_CR18","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.biopsych.2016.10.012","volume":"82","author":"SW Black","year":"2017","unstructured":"Black SW et al (2017) Trace amine-associated receptor 1 agonists as narcolepsy therapeutics. Biol Psychiatry 82:623\u2013633","journal-title":"Biol Psychiatry"},{"key":"821_CR19","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/dom.12932","volume":"19","author":"J Blundell","year":"2017","unstructured":"Blundell J et al (2017) Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab 19:1242\u20131251","journal-title":"Diabetes Obes Metab"},{"key":"821_CR20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1476-5381.1990.tb12072.x","volume":"100","author":"R Bouhelal","year":"1990","unstructured":"Bouhelal R, Loubati\u00e8res-Mariani MM, Mir AK (1990) Investigation of the mechanism(s) of 8-OH-DPAT-mediated inhibition of plasma insulin in spontaneously hypertensive rats. Br J Pharmacol 100:173\u2013179","journal-title":"Br J Pharmacol"},{"key":"821_CR21","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","volume":"27","author":"JB Buse","year":"2004","unstructured":"Buse JB et al (2004) Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27:2628\u20132635","journal-title":"Diabetes Care"},{"key":"821_CR22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","volume":"374","author":"JB Buse","year":"2009","unstructured":"Buse JB et al (2009) Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374:39\u201347","journal-title":"Lancet"},{"key":"821_CR23","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/B978-1-4377-0324-5.00031-6","volume-title":"Williams textbook of endocrinology (Twelfth Edition)","author":"JB Buse","year":"2011","unstructured":"Buse JB, Polonsky KS, Burant CF (2011) CHAPTER 31 \u2013 Type 2 diabetes mellitus. In: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM (eds) Williams textbook of endocrinology (Twelfth Edition). W.B. Saunders, Philadelphia, pp 1371\u20131435"},{"key":"821_CR24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.tcm.2021.12.008","volume":"33","author":"AM Chao","year":"2023","unstructured":"Chao AM et al (2023) Semaglutide for the treatment of obesity. Trends Cardiovasc Med 33:159\u2013166","journal-title":"Trends Cardiovasc Med"},{"key":"821_CR25","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.3390\/ijms25073832","volume":"25","author":"LG Chrysavgis","year":"2024","unstructured":"Chrysavgis LG et al (2024) Glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide, and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: novel medication in new liver disease nomenclature. Int J Mol Sci 25:3832","journal-title":"Int J Mol Sci"},{"key":"821_CR26","doi-asserted-by":"crossref","first-page":"e170671","DOI":"10.1172\/jci.insight.170671","volume":"8","author":"V Chuong","year":"2023","unstructured":"Chuong V et al (2023) The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight 8:e170671","journal-title":"JCI Insight"},{"key":"821_CR27","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.3390\/nu13041158","volume":"13","author":"L Cifuentes","year":"2021","unstructured":"Cifuentes L, Camilleri M, Acosta A (2021) Gastric sensory and motor functions and energy intake in health and obesity-therapeutic implications. Nutrients 13:1158","journal-title":"Nutrients"},{"key":"821_CR28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41537-021-00190-z","volume":"7","author":"CU Correll","year":"2021","unstructured":"Correll CU et al (2021) Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study. NPJ Schizophr 7:63","journal-title":"NPJ Schizophr"},{"key":"821_CR29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fnins.2015.00039","volume":"9","author":"R Cotter","year":"2015","unstructured":"Cotter R et al (2015) The trace amine-associated receptor 1 modulates methamphetamine\u2019s neurochemical and behavioral effects. Front Neurosci 9:39","journal-title":"Front Neurosci"},{"key":"821_CR30","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.113685","volume":"171","author":"MJ Cripps","year":"2020","unstructured":"Cripps MJ et al (2020) Identification of a subset of trace amine-associated receptors and ligands as potential modulators of insulin secretion. Biochem Pharmacol 171:113685","journal-title":"Biochem Pharmacol"},{"key":"821_CR31","volume":"16","author":"C Dagher","year":"2024","unstructured":"Dagher C et al (2024) Semaglutide-induced acute pancreatitis leading to death after four years of use. Cureus 16:e69704","journal-title":"Cureus"},{"key":"821_CR32","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.2147\/NDT.S113099","volume":"13","author":"M Dayabandara","year":"2017","unstructured":"Dayabandara M et al (2017) Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat 13:2231\u20132241","journal-title":"Neuropsychiatr Dis Treat"},{"key":"821_CR33","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.101883","volume":"80","author":"N Dedic","year":"2024","unstructured":"Dedic N et al (2024) TAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding. Mol Metab 80:101883","journal-title":"Mol Metab"},{"key":"821_CR34","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","volume":"28","author":"RA DeFronzo","year":"2005","unstructured":"DeFronzo RA et al (2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28:1092\u20131100","journal-title":"Diabetes Care"},{"key":"821_CR35","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00592-022-01936-6","volume":"59","author":"U Di Folco","year":"2022","unstructured":"Di Folco U et al (2022) Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes. Acta Diabetol 59:1287\u20131294","journal-title":"Acta Diabetol"},{"key":"821_CR36","first-page":"90","volume":"10","author":"Y Duan","year":"2022","unstructured":"Duan Y, Wan Z (2022) Discovery and development of semaglutide. Prevalence 10:90","journal-title":"Prevalence"},{"key":"821_CR37","volume":"8","author":"E Egecioglu","year":"2013","unstructured":"Egecioglu E, Engel JA, Jerlhag E (2013a) The glucagon-like peptide 1 analogue, exendin-4, attenuates the rewarding properties of psychostimulant drugs in mice. PLoS One 8:e69010","journal-title":"PLoS One"},{"key":"821_CR38","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.psyneuen.2012.11.009","volume":"38","author":"E Egecioglu","year":"2013","unstructured":"Egecioglu E et al (2013b) The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents. Psychoneuroendocrinology 38:1259\u20131270","journal-title":"Psychoneuroendocrinology"},{"key":"821_CR39","first-page":"131","volume":"8","author":"L Fala","year":"2015","unstructured":"Fala L (2015) Trulicity (dulaglutide): a new GLP-1 receptor agonist once-weekly subcutaneous injection approved for the treatment of patients with type 2 diabetes. Am Health Drug Benefits 8:131\u2013134","journal-title":"Am Health Drug Benefits"},{"key":"821_CR40","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.sleep.2022.11.022","volume":"101","author":"JC Feemster","year":"2023","unstructured":"Feemster JC et al (2023) Treatment with the novel TAAR1 agonist ulotaront is associated with reductions in quantitative polysomnographic REM sleep without atonia in healthy human subjects: Results of a post-hoc analysis. Sleep Med 101:578\u2013586","journal-title":"Sleep Med"},{"key":"821_CR9001","doi-asserted-by":"crossref","unstructured":"Ferragud A et al (2017) The Trace Amine-Associated Receptor 1 Agonist RO5256390 Blocks Compulsive, Bingelike Eating in Rats. Neuropsychopharmacology 42:1458\u20131470","DOI":"10.1038\/npp.2016.233"},{"key":"821_CR41","volume-title":"StatPearls","author":"AM Freeman","year":"2024","unstructured":"Freeman AM, Acevedo LA, Pennings N (2024) Insulin Resistance. In: StatPearls. StatPearls Publishing LLC, Treasure Island (FL)"},{"key":"821_CR42","doi-asserted-by":"crossref","DOI":"10.1111\/adb.13285","volume":"28","author":"BA Frycz","year":"2023","unstructured":"Frycz BA et al (2023) Activation of trace amine-associated receptor 1 (TAAR1) transiently reduces alcohol drinking in socially housed mice. Addict Biol 28:e13285","journal-title":"Addict Biol"},{"key":"821_CR43","doi-asserted-by":"crossref","first-page":"e133429","DOI":"10.1172\/jci.insight.133429","volume":"5","author":"S Gabery","year":"2021","unstructured":"Gabery S et al (2021) Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight 5:e133429","journal-title":"JCI Insight"},{"key":"821_CR44","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1124\/pr.117.015305","volume":"70","author":"RR Gainetdinov","year":"2018","unstructured":"Gainetdinov RR, Hoener MC, Berry MD (2018) Trace amines and their receptors. Pharmacol Rev 70:549\u2013620","journal-title":"Pharmacol Rev"},{"key":"821_CR45","first-page":"1","volume":"21","author":"U Galicia-Garcia","year":"2020","unstructured":"Galicia-Garcia U et al (2020) Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci 21:1\u201334","journal-title":"Int J Mol Sci"},{"key":"821_CR46","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1042\/bj20020999","volume":"368","author":"Z Gao","year":"2002","unstructured":"Gao Z et al (2002) Protein kinase A translocation and insulin secretion in pancreatic beta-cells: studies with adenylate cyclase toxin from Bordetella pertussis. Biochem J 368:397\u2013404","journal-title":"Biochem J"},{"key":"821_CR47","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(08)61246-5","volume":"373","author":"A Garber","year":"2009","unstructured":"Garber A et al (2009) Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373:473\u2013481","journal-title":"Lancet"},{"key":"821_CR48","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey WT et al (2022) Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 28:2083\u20132091","journal-title":"Nat Med"},{"key":"821_CR49","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/01.tp.0000251379.46596.2d","volume":"83","author":"KA Ghofaili","year":"2007","unstructured":"Ghofaili KA et al (2007) Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes. Transplantation 83:24\u201328","journal-title":"Transplantation"},{"key":"821_CR50","doi-asserted-by":"crossref","first-page":"e2231982","DOI":"10.1001\/jamanetworkopen.2022.31982","volume":"5","author":"W Ghusn","year":"2022","unstructured":"Ghusn W et al (2022) Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity. JAMA Netw Open 5:e2231982\u2013e2231982","journal-title":"JAMA Netw Open"},{"key":"821_CR51","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2337\/dc14-1625","volume":"38","author":"F Giorgino","year":"2015","unstructured":"Giorgino F et al (2015) Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care 38:2241\u20132249","journal-title":"Diabetes Care"},{"key":"821_CR52","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.schres.2013.02.023","volume":"146","author":"MD Guenette","year":"2013","unstructured":"Guenette MD et al (2013) Atypical antipsychotics and effects of adrenergic and serotonergic receptor binding on insulin secretion in-vivo: an animal model. Schizophr Res 146:162\u2013169","journal-title":"Schizophr Res"},{"key":"821_CR53","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1007\/s00259-025-07564-w","volume":"53","author":"A Haider","year":"2026","unstructured":"Haider A et al (2026) Preclinical development of [18F]TAAR1-2203 as a PET radioligand for imaging TAAR1 expression and receptor occupancy. Eur J Nucl Med Mol Imaging 53:2540\u20132553","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"821_CR54","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.tins.2022.10.010","volume":"46","author":"EF Halff","year":"2023","unstructured":"Halff EF et al (2023) Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders. Trends Neurosci 46:60\u201374","journal-title":"Trends Neurosci"},{"key":"821_CR55","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1172\/JCI18581","volume":"112","author":"AM Hennige","year":"2003","unstructured":"Hennige AM et al (2003) Upregulation of insulin receptor substrate-2 in pancreatic beta cells prevents diabetes. J Clin Invest 112:1521\u20131532","journal-title":"J Clin Invest"},{"key":"821_CR56","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/bph.15611","volume":"179","author":"JJ Holst","year":"2022","unstructured":"Holst JJ, Andersen DB, Grunddal KV (2022) Actions of glucagon-like peptide-1 receptor ligands in the gut. Br J Pharmacol 179:727\u2013742","journal-title":"Br J Pharmacol"},{"key":"821_CR57","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2025.110460","volume":"274","author":"C Houdant","year":"2025","unstructured":"Houdant C et al (2025) Trace amine-associated receptor 1 agonists reduce alcohol drinking and differentially modulate dopamine release in the nucleus accumbens of alcohol preferring mice. Neuropharmacology 274:110460","journal-title":"Neuropharmacology"},{"key":"821_CR58","doi-asserted-by":"crossref","unstructured":"Howes OD et al (2025) The trace amine-associated receptor 1 regulates presynaptic dopamine function: evidence from preclinical studies and a phase 1b trial in patients with schizophrenia. Biol Psychiatry","DOI":"10.1016\/j.biopsych.2025.10.013"},{"key":"821_CR59","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1756-6606-6-46","volume":"6","author":"Y-S Hsieh","year":"2013","unstructured":"Hsieh Y-S et al (2013) The neuropeptide Y Y1 receptor knockdown modulates activator protein 1-involved feeding behavior in amphetamine-treated rats. Mol Brain 6:46","journal-title":"Mol Brain"},{"key":"821_CR60","volume":"107","author":"JK Huey","year":"2025","unstructured":"Huey JK et al (2025) Trace amine\u2013associated receptor 1 agonists differentially regulate dopamine transporter function. Mol Pharmacol 107:100064","journal-title":"Mol Pharmacol"},{"key":"821_CR61","volume":"16","author":"K Hughes","year":"2024","unstructured":"Hughes K et al (2024) Acute Pancreatitis Likely Due to Semaglutide. Cureus 16:e69844","journal-title":"Cureus"},{"key":"821_CR62","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1210\/en.2002-220897","volume":"144","author":"H Hui","year":"2003","unstructured":"Hui H et al (2003) Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5\u2032-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 144:1444\u20131455","journal-title":"Endocrinology"},{"key":"821_CR63","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1177\/02698811251319457","volume":"39","author":"ME Jensen","year":"2025","unstructured":"Jensen ME et al (2025) Single-dose psilocybin therapy for alcohol use disorder: pharmacokinetics, feasibility, safety and efficacy in an open-label study. J Psychopharmacol 39:463\u2013473","journal-title":"J Psychopharmacol"},{"key":"821_CR64","doi-asserted-by":"crossref","first-page":"bqaf028","DOI":"10.1210\/endocr\/bqaf028","volume":"166","author":"E Jerlhag","year":"2025","unstructured":"Jerlhag E (2025) GLP-1 receptor agonists: promising therapeutic targets for alcohol use disorder. Endocrinology 166:bqaf028","journal-title":"Endocrinology"},{"key":"821_CR65","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1111\/jcmm.13259","volume":"22","author":"K Kapodistria","year":"2018","unstructured":"Kapodistria K et al (2018) Liraglutide, a human glucagon-like peptide-1 analogue, stimulates AKT-dependent survival signalling and inhibits pancreatic \u03b2-cell apoptosis. J Cell Mol Med 22:2970\u20132980","journal-title":"J Cell Mol Med"},{"key":"821_CR66","doi-asserted-by":"crossref","first-page":"772","DOI":"10.3390\/jcm12030772","volume":"12","author":"C Kennedy","year":"2023","unstructured":"Kennedy C et al (2023) The effect of semaglutide on blood pressure in patients without diabetes: a systematic review and meta-analysis. J Clin Med 12:772","journal-title":"J Clin Med"},{"key":"821_CR67","first-page":"100290","volume":"27","author":"S Khare","year":"2022","unstructured":"Khare S et al (2022) Cystic fibrosis-related diabetes: prevalence, screening, and diagnosis. J Clin Transl Endocrinol 27:100290\u2013100294","journal-title":"J Clin Transl Endocrinol"},{"key":"821_CR68","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/B978-0-323-29738-7.00036-8","volume-title":"Williams textbook of endocrinology (Thirteenth Edition)","author":"S Klein","year":"2016","unstructured":"Klein S, Romijn JA (2016) Chapter 36 \u2013 Obesity. In: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM (eds) Williams textbook of endocrinology (Thirteenth Edition). Elsevier, Philadelphia, pp 1633\u20131659"},{"key":"821_CR69","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1742-1241.2010.02499.x","volume":"64","author":"LB Knudsen","year":"2010","unstructured":"Knudsen LB (2010) Liraglutide: the therapeutic promise from animal models. Int J Clin Pract Suppl 64:4\u201311","journal-title":"Int J Clin Pract Suppl"},{"key":"821_CR70","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/B978-0-323-91141-2.00003-9","volume-title":"Steroid hormone receptors in health and disease","author":"R Kumar","year":"2024","unstructured":"Kumar R, McEwan IJ (2024) Chapter 3 \u2013 Steroids and cardiovascular and metabolic disorders. In: Kumar R, McEwan IJ (eds) Steroid hormone receptors in health and disease. Academic Press, pp 29\u201353"},{"key":"821_CR71","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/jamapsychiatry.2024.3599","volume":"82","author":"M L\u00e4hteenvuo","year":"2025","unstructured":"L\u00e4hteenvuo M et al (2025) Repurposing semaglutide and liraglutide for alcohol use disorder. JAMA Psychiatry 82:94\u201398","journal-title":"JAMA Psychiatry"},{"key":"821_CR72","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ejphar.2015.06.026","volume":"763","author":"VM Lam","year":"2015","unstructured":"Lam VM et al (2015) In-vivo pharmacology of trace-amine associated receptor 1. Eur J Pharmacol 763:136\u2013142","journal-title":"Eur J Pharmacol"},{"key":"821_CR73","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.7861\/clinmed.2021-0369","volume":"21","author":"YN Lee","year":"2021","unstructured":"Lee YN, Huda MS (2021) Uncommon forms of diabetes. Clin Med (Lond) 21:e337\u2013e341","journal-title":"Clin Med (Lond)"},{"key":"821_CR74","first-page":"55","volume-title":"Diabetes epidemiology, genetics, pathogenesis, diagnosis, prevention, and treatment","author":"SH Ley","year":"2018","unstructured":"Ley SH, Meigs JB (2018) Epidemiology and risk factors of type 2 diabetes. In: Bonora E, DeFronzo RA (eds) Diabetes epidemiology, genetics, pathogenesis, diagnosis, prevention, and treatment. Springer International Publishing, Cham, pp 55\u201380"},{"key":"821_CR9002","doi-asserted-by":"crossref","unstructured":"Li JR et al (2023) Case Report: Semaglutide-associated depression: a report of two cases. Front Psychiatry 14:1238353","DOI":"10.3389\/fpsyt.2023.1238353"},{"key":"821_CR75","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/ijnp\/pyae059.007","volume":"28","author":"J-X Li","year":"2025","unstructured":"Li J-X (2025) TAAR1 agonists AS potential anti-addiction candidates: preclinical evidence. Int J Neuropsychopharmacol 28:i4\u2013i5","journal-title":"Int J Neuropsychopharmacol"},{"key":"821_CR76","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3389\/fphar.2018.00279","volume":"9","author":"JF Liu","year":"2018","unstructured":"Liu JF, Li JX (2018) TAAR1 in addiction: looking beyond the tip of the iceberg. Front Pharmacol 9:279","journal-title":"Front Pharmacol"},{"key":"821_CR77","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1038\/s41386-018-0017-9","volume":"43","author":"JF Liu","year":"2018","unstructured":"Liu JF et al (2018) Role of trace amine-associated receptor 1 in nicotine's behavioral and neurochemical effects. Neuropsychopharmacology 43:2435\u20132444","journal-title":"Neuropsychopharmacology"},{"key":"821_CR78","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1038\/s41380-022-01448-3","volume":"27","author":"J Liu","year":"2022","unstructured":"Liu J et al (2022) TAAR1 regulates drug-induced reinstatement of cocaine-seeking via negatively modulating CaMKII\u03b1 activity in the NAc. Mol Psychiatry 27:2136\u20132145","journal-title":"Mol Psychiatry"},{"key":"821_CR79","doi-asserted-by":"crossref","first-page":"10033","DOI":"10.3390\/ijms262010033","volume":"26","author":"M Marcinkowska","year":"2025","unstructured":"Marcinkowska M et al (2025) JP-14: a trace amine-associated receptor 1 agonist with anti-metabolic disorder potential. Int J Mol Sci 26:10033","journal-title":"Int J Mol Sci"},{"key":"821_CR80","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1055\/s-2006-956505","volume":"38","author":"A Mari","year":"2006","unstructured":"Mari A et al (2006) Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea. Horm Metab Res 38:838\u2013844","journal-title":"Horm Metab Res"},{"key":"821_CR81","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"P Marso Steven","year":"2016","unstructured":"Marso Steven P et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834\u20131844","journal-title":"N Engl J Med"},{"key":"821_CR82","doi-asserted-by":"crossref","unstructured":"Martinelli S, Petrucciani N (2025) Modulating reward circuits through GLP-1 signaling: implications for behavioral and substance addictions. Psychopharmacology","DOI":"10.1007\/s00213-025-06989-3"},{"key":"821_CR83","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.121268","volume":"313","author":"FF Martins","year":"2023","unstructured":"Martins FF et al (2023) Hypothalamic anorexigenic signaling pathways (leptin, amylin, and proopiomelanocortin) are semaglutide (GLP-1 analog) targets in obesity control in mice. Life Sci 313:121268","journal-title":"Life Sci"},{"key":"821_CR84","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/1060028017689878","volume":"51","author":"D McCarty","year":"2017","unstructured":"McCarty D, Coleman M, Boland CL (2017) Lixisenatide: a new daily GLP-1 agonist for type 2 diabetes management. Ann Pharmacother 51:401\u2013409","journal-title":"Ann Pharmacother"},{"key":"821_CR85","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1074\/jbc.RA118.005464","volume":"294","author":"ES Michael","year":"2019","unstructured":"Michael ES, Covic L, Kuliopulos A (2019) Trace amine-associated receptor 1 (TAAR1) promotes anti-diabetic signaling in insulin-secreting cells. J Biol Chem 294:4401\u20134411","journal-title":"J Biol Chem"},{"key":"821_CR86","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1111\/dom.15569","volume":"26","author":"S Milanovi\u0107","year":"2024","unstructured":"Milanovi\u0107 S et al (2024) TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetes. Diabetes Obes Metab 26:2466\u20132475","journal-title":"Diabetes Obes Metab"},{"key":"821_CR87","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/dom.70110","volume":"28","author":"S Milanovic","year":"2026","unstructured":"Milanovic S et al (2026) A double-blind study on ulotaront\u2019s impact on weight-related parameters in schizophrenia patients with metabolic syndrome and prediabetes: part II. Diabetes Obes Metab 28:94\u2013102","journal-title":"Diabetes Obes Metab"},{"key":"821_CR88","volume":"156","author":"TP Minari","year":"2026","unstructured":"Minari TP, de Ara\u00fajo Filho GM, Pisani LP (2026) Exploring reward sensitivity as a central mechanism in binge-eating behavior. J Nutr 156:101294","journal-title":"J Nutr"},{"key":"821_CR89","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/B978-0-12-385157-4.01212-4","volume-title":"Encyclopedia of the Neurological Sciences (Second Edition)","author":"CV Mobbs","year":"2014","unstructured":"Mobbs CV (2014) Obesity. In: Aminoff MJ, Daroff RB (eds) Encyclopedia of the Neurological Sciences (Second Edition). Academic Press, Oxford, pp 621\u2013622"},{"key":"821_CR90","doi-asserted-by":"crossref","DOI":"10.1016\/j.focha.2023.100335","volume":"3","author":"SM Mohamed","year":"2023","unstructured":"Mohamed SM et al (2023) Metabolic syndrome: risk factors, diagnosis, pathogenesis, and management with natural approaches. Food Chem Adv 3:100335","journal-title":"Food Chem Adv"},{"key":"821_CR91","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.amjmed.2025.01.021","volume":"138","author":"A Moiz","year":"2025","unstructured":"Moiz A et al (2025) Mechanisms of GLP-1 receptor agonist-induced weight loss: a review of central and peripheral pathways in appetite and energy regulation. Am J Med 138:934\u2013940","journal-title":"Am J Med"},{"key":"821_CR92","doi-asserted-by":"crossref","first-page":"E24","DOI":"10.5888\/pcd14.160287","volume":"14","author":"JX Moore","year":"2017","unstructured":"Moore JX, Chaudhary N, Akinyemiju T (2017) Metabolic syndrome prevalence by race\/ethnicity and sex in the United States, National Health and Nutrition Examination Survey, 1988-2012. Prev Chronic Dis 14:E24","journal-title":"Prev Chronic Dis"},{"key":"821_CR93","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3389\/fphar.2018.00129","volume":"9","author":"CF Moore","year":"2018","unstructured":"Moore CF, Sabino V, Cottone P (2018) Trace Amine Associated Receptor 1 (TAAR1) modulation of food reward. Front Pharmacol 9:129","journal-title":"Front Pharmacol"},{"key":"821_CR94","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3389\/fphar.2017.00807","volume":"8","author":"J M\u00fchlhaus","year":"2017","unstructured":"M\u00fchlhaus J et al (2017) Investigation of naturally occurring single-nucleotide variants in human TAAR1. Front Pharmacol 8:807","journal-title":"Front Pharmacol"},{"key":"821_CR95","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck MA et al (2021) GLP-1 receptor agonists in the treatment of type 2 diabetes \u2013 state-of-the-art. Mol Metab 46:101102","journal-title":"Mol Metab"},{"key":"821_CR96","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.109924","volume":"188","author":"JJ Noubiap","year":"2022","unstructured":"Noubiap JJ et al (2022) Geographic distribution of metabolic syndrome and its components in the general adult population: A meta-analysis of global data from 28 million individuals. Diabetes Res Clin Pract 188:109924","journal-title":"Diabetes Res Clin Pract"},{"key":"821_CR97","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5001\/omj.2012.68","volume":"27","author":"AB Olokoba","year":"2012","unstructured":"Olokoba AB, Obateru OA, Olokoba LB (2012) Type 2 diabetes mellitus: a review of current trends. Oman Med J 27:269\u2013273","journal-title":"Oman Med J"},{"key":"821_CR98","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s00125-017-4315-2","volume":"60","author":"A \u00d8rgaard","year":"2017","unstructured":"\u00d8rgaard A, Holst JJ (2017) The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice. Diabetologia 60:1731\u20131739","journal-title":"Diabetologia"},{"key":"821_CR99","volume":"6","author":"VA Palzes","year":"2026","unstructured":"Palzes VA et al (2026) Glucagon-like peptide-1 receptor agonists and alcohol use: a real-word observational study in a large, integrated health care system. Biol Psychiatry Glob Open Sci 6:100659","journal-title":"Biol Psychiatry Glob Open Sci"},{"key":"821_CR100","first-page":"5219","volume":"14","author":"B Pang","year":"2017","unstructured":"Pang B et al (2017) Glucagon-like peptide-1 potentiates glucose-stimulated insulin secretion via the transient receptor potential melastatin 2 channel. Exp Ther Med 14:5219\u20135227","journal-title":"Exp Ther Med"},{"key":"821_CR101","doi-asserted-by":"crossref","first-page":"11351","DOI":"10.3390\/ijms252111351","volume":"25","author":"S Park","year":"2024","unstructured":"Park S et al (2024) Wakefulness induced by TAAR1 partial agonism in mice is mediated through dopaminergic neurotransmission. Int J Mol Sci 25:11351","journal-title":"Int J Mol Sci"},{"key":"821_CR102","volume":"15","author":"F Patel","year":"2023","unstructured":"Patel F et al (2023) Acute pancreatitis in a patient taking semaglutide. Cureus 15:e43773","journal-title":"Cureus"},{"key":"821_CR103","first-page":"agaf069","volume":"61","author":"S Patel","year":"2025","unstructured":"Patel S et al (2025) GLP-1 receptor agonists and alcohol use disorder: a systematic review. Alcohol Alcohol 61:agaf069","journal-title":"Alcohol Alcohol"},{"key":"821_CR104","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1038\/npp.2014.88","volume":"39","author":"Y Pei","year":"2014","unstructured":"Pei Y et al (2014) Activation of the trace amine-associated receptor 1 prevents relapse to cocaine seeking. Neuropsychopharmacology 39:2299\u20132308","journal-title":"Neuropsychopharmacology"},{"key":"821_CR105","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","volume":"7","author":"T Pillinger","year":"2020","unstructured":"Pillinger T et al (2020) Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry 7:64\u201377","journal-title":"Lancet Psychiatry"},{"key":"821_CR106","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.amjmed.2013.06.007","volume":"126","author":"RE Pratley","year":"2013","unstructured":"Pratley RE (2013) The early treatment of type 2 diabetes. Am J Med 126:S2\u2013S9","journal-title":"Am J Med"},{"key":"821_CR107","doi-asserted-by":"crossref","first-page":"20998","DOI":"10.1038\/s41598-023-48267-2","volume":"13","author":"F Quddos","year":"2023","unstructured":"Quddos F et al (2023) Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity. Sci Rep 13:20998","journal-title":"Sci Rep"},{"key":"821_CR108","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.molmet.2015.09.015","volume":"5","author":"S Raab","year":"2016","unstructured":"Raab S et al (2016) Incretin-like effects of small molecule trace amine-associated receptor 1 agonists. Mol Metab 5:47\u201356","journal-title":"Mol Metab"},{"key":"821_CR109","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/mp.2012.57","volume":"18","author":"FG Revel","year":"2013","unstructured":"Revel FG et al (2013) A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight. Mol Psychiatry 18:543\u2013556","journal-title":"Mol Psychiatry"},{"key":"821_CR110","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1210\/clinem\/dgab065","volume":"106","author":"MC Riddle","year":"2021","unstructured":"Riddle MC et al (2021) Efficacy and safety of dulaglutide in older patients: a post hoc analysis of the REWIND trial. J Clin Endocrinol Metab 106:1345\u20131351","journal-title":"J Clin Endocrinol Metab"},{"key":"821_CR111","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/1753944717711379","volume":"11","author":"Y Rochlani","year":"2017","unstructured":"Rochlani Y et al (2017) Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Ther Adv Cardiovasc Dis 11:215\u2013225","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"821_CR112","doi-asserted-by":"crossref","unstructured":"Rode AKO et al (2022) Induced human regulatory T cells express the glucagon-like peptide-1 receptor. Cells 11","DOI":"10.3390\/cells11162587"},{"key":"821_CR113","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3389\/fphar.2017.00987","volume":"8","author":"G Rutigliano","year":"2018","unstructured":"Rutigliano G, Accorroni A, Zucchi R (2018) The case for TAAR1 as a modulator of central nervous system function. Front Pharmacol 8:987","journal-title":"Front Pharmacol"},{"key":"821_CR114","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.3389\/fphar.2019.01027","volume":"10","author":"G Rutigliano","year":"2019","unstructured":"Rutigliano G et al (2019) Non-functional trace amine-associated receptor 1 variants in patients with mental disorders. Front Pharmacol 10:1027","journal-title":"Front Pharmacol"},{"key":"821_CR115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21062005","volume":"21","author":"G Rutigliano","year":"2020","unstructured":"Rutigliano G et al (2020) 3-Iodothyronamine and derivatives: new allies against metabolic syndrome? Int J Mol Sci 21:1\u201319","journal-title":"Int J Mol Sci"},{"key":"821_CR116","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/s41591-024-02996-7","volume":"30","author":"DH Ryan","year":"2024","unstructured":"Ryan DH et al (2024) Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med 30:2049\u20132057","journal-title":"Nat Med"},{"key":"821_CR117","doi-asserted-by":"crossref","first-page":"e2423385","DOI":"10.1001\/jamanetworkopen.2024.23385","volume":"7","author":"G Schoretsanitis","year":"2024","unstructured":"Schoretsanitis G et al (2024) Disproportionality analysis from World Health Organization data on semaglutide, liraglutide, and suicidality. JAMA Netw Open 7:e2423385","journal-title":"JAMA Netw Open"},{"key":"821_CR118","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/npp.2016.216","volume":"42","author":"MD Schwartz","year":"2017","unstructured":"Schwartz MD et al (2017) Trace amine-associated receptor 1 regulates wakefulness and EEG spectral composition. Neuropsychopharmacology 42:1305\u20131314","journal-title":"Neuropsychopharmacology"},{"key":"821_CR119","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.2040-1124.2010.00022.x","volume":"1","author":"Y Seino","year":"2010","unstructured":"Seino Y, Fukushima M, Yabe D (2010) GIP and GLP-1, the two incretin hormones: Similarities and differences. J Diabetes Investig 1:8\u201323","journal-title":"J Diabetes Investig"},{"key":"821_CR120","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1124\/mol.119.116798","volume":"96","author":"X Shi","year":"2019","unstructured":"Shi X et al (2019) Activation of trace amine-associated receptor 1 stimulates an antiapoptotic signal cascade via extracellular signal-regulated kinase 1\/2. Mol Pharmacol 96:493\u2013504","journal-title":"Mol Pharmacol"},{"key":"821_CR121","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2024.171179","volume":"175","author":"AH Shilleh","year":"2024","unstructured":"Shilleh AH et al (2024) GLP1R and GIPR expression and signaling in pancreatic alpha cells, beta cells and delta cells. Peptides 175:171179","journal-title":"Peptides"},{"key":"821_CR122","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102920","volume":"78","author":"M Subhani","year":"2024","unstructured":"Subhani M et al (2024) Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption: a systematic review. EClinicalMedicine 78:102920","journal-title":"EClinicalMedicine"},{"key":"821_CR123","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11892-015-0704-4","volume":"16","author":"J Suvisaari","year":"2016","unstructured":"Suvisaari J et al (2016) Diabetes and Schizophrenia. Curr Diab Rep 16:16","journal-title":"Curr Diab Rep"},{"key":"821_CR124","doi-asserted-by":"crossref","unstructured":"Tamayo-Trujillo R et al (2024) Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity. Front Nutr:11\u20132024","DOI":"10.3389\/fnut.2024.1398059"},{"key":"821_CR125","doi-asserted-by":"crossref","DOI":"10.1111\/jne.70070","volume":"37","author":"ZH Tharwani","year":"2025","unstructured":"Tharwani ZH et al (2025) Exploring the link between dopamine dysregulation and eating disorders: a narrative review. J Neuroendocrinol 37:e70070","journal-title":"J Neuroendocrinol"},{"key":"821_CR126","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1038\/npp.2014.91","volume":"39","author":"DA Thorn","year":"2014","unstructured":"Thorn DA et al (2014) Effects of the trace amine-associated receptor 1 agonist RO5263397 on abuse-related effects of cocaine in rats. Neuropsychopharmacology 39:2309\u20132316","journal-title":"Neuropsychopharmacology"},{"key":"821_CR127","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1749-6632.2000.tb06972.x","volume":"921","author":"K Tr\u00dcMper","year":"2000","unstructured":"Tr\u00dcMper K et al (2000) Integrative mitogenic role of protein kinase B\/Akt in \u03b2-cells. Ann N Y Acad Sci 921:242\u2013250","journal-title":"Ann N Y Acad Sci"},{"key":"821_CR128","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.2964","volume":"8","author":"S Tsipas","year":"2025","unstructured":"Tsipas S et al (2025) Spending on glucagon-like peptide-1 receptor agonists among US adults. JAMA Netw Open 8:e252964","journal-title":"JAMA Netw Open"},{"key":"821_CR129","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/s41380-019-0469-2","volume":"26","author":"SM Underhill","year":"2021","unstructured":"Underhill SM et al (2021) Amphetamines signal through intracellular TAAR1 receptors coupled to G\u03b1(13) and G\u03b1(S) in discrete subcellular domains. Mol Psychiatry 26:1208\u20131223","journal-title":"Mol Psychiatry"},{"key":"821_CR130","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.3390\/biom13111618","volume":"13","author":"AN Vaganova","year":"2023","unstructured":"Vaganova AN et al (2023) Trace amine-associated receptors and monoamine-mediated regulation of insulin secretion in pancreatic islets. Biomolecules 13:1618","journal-title":"Biomolecules"},{"key":"821_CR131","first-page":"1590","volume":"12","author":"AN Vaganova","year":"2024","unstructured":"Vaganova AN et al (2024) Dopamine receptors and TAAR1 functional interaction patterns in the duodenum are impaired in gastrointestinal disorders. Biomedicine 12:1590","journal-title":"Biomedicine"},{"key":"821_CR132","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/adb.12295","volume":"21","author":"D Vall\u00f6f","year":"2016","unstructured":"Vall\u00f6f D et al (2016) The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents. Addict Biol 21:422\u2013437","journal-title":"Addict Biol"},{"key":"821_CR133","first-page":"76","volume":"9","author":"J Vidal","year":"2013","unstructured":"Vidal J (2013) Lixisenatide - a new glucagon-like peptide 1 receptor agonist in the treatment of type 2 diabetes. Eur Endocrinol 9:76\u201381","journal-title":"Eur Endocrinol"},{"key":"821_CR134","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1001\/jamainternmed.2024.4346","volume":"184","author":"TA Wadden","year":"2024","unstructured":"Wadden TA et al (2024) Psychiatric safety of semaglutide for weight management in people without known major psychopathology: post hoc analysis of the STEP 1, 2, 3, and 5 trials. JAMA Intern Med 184:1290\u20131300","journal-title":"JAMA Intern Med"},{"key":"821_CR135","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s00125-004-1327-5","volume":"47","author":"Q Wang","year":"2004","unstructured":"Wang Q et al (2004) Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells. Diabetologia 47:478\u2013487","journal-title":"Diabetologia"},{"key":"821_CR136","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1038\/s41467-024-48780-6","volume":"15","author":"W Wang","year":"2024","unstructured":"Wang W et al (2024) Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nat Commun 15:4548","journal-title":"Nat Commun"},{"key":"821_CR137","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/bph.15535","volume":"179","author":"DL Williams","year":"2022","unstructured":"Williams DL (2022) The diverse effects of brain glucagon-like peptide 1 receptors on ingestive behaviour. Br J Pharmacol 179:571\u2013583","journal-title":"Br J Pharmacol"},{"key":"821_CR138","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.7150\/ijms.10001","volume":"11","author":"Y Wu","year":"2014","unstructured":"Wu Y et al (2014) Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention. Int J Med Sci 11:1185\u20131200","journal-title":"Int J Med Sci"},{"key":"821_CR139","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/bs.apha.2021.10.005","volume":"93","author":"R Wu","year":"2022","unstructured":"Wu R, Liu J, Li JX (2022) Trace amine-associated receptor 1 and drug abuse. Adv Pharmacol 93:373\u2013401","journal-title":"Adv Pharmacol"},{"key":"821_CR140","volume":"11","author":"S Xie","year":"2022","unstructured":"Xie S et al (2022) Long-term activation of glucagon-like peptide-1 receptor by dulaglutide prevents diabetic heart failure and metabolic remodeling in type 2 diabetes. J Am Heart Assoc 11:e026728","journal-title":"J Am Heart Assoc"},{"key":"821_CR141","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10571-019-00774-5","volume":"40","author":"Z Xu","year":"2020","unstructured":"Xu Z, Li Q (2020) TAAR Agonists. Cell Mol Neurobiol 40:257\u2013272","journal-title":"Cell Mol Neurobiol"},{"key":"821_CR142","doi-asserted-by":"crossref","DOI":"10.1016\/j.dci.2024.105171","volume":"156","author":"Y Yang","year":"2024","unstructured":"Yang Y et al (2024) A trace amine associated receptor mediates antimicrobial immune response in the oyster Crassostrea gigas. Dev Comp Immunol 156:105171","journal-title":"Dev Comp Immunol"},{"key":"821_CR143","doi-asserted-by":"crossref","first-page":"995007","DOI":"10.3389\/fendo.2022.995007","volume":"13","author":"L Yue","year":"2022","unstructured":"Yue L et al (2022) Effects of semaglutide on vascular structure and proteomics in high-fat diet-induced obese mice. Front Endocrinol 13:995007","journal-title":"Front Endocrinol"},{"key":"821_CR144","first-page":"1","volume":"14","author":"X Zhao","year":"2023","unstructured":"Zhao X et al (2023) The crucial role and mechanism of insulin resistance in metabolic disease. Front Endocrinol 14:1\u201324","journal-title":"Front Endocrinol"},{"key":"821_CR145","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/sj.bjp.0706948","volume":"149","author":"R Zucchi","year":"2006","unstructured":"Zucchi R et al (2006) Trace amine-associated receptors and their ligands. Br J Pharmacol 149:967\u2013978","journal-title":"Br J Pharmacol"}],"container-title":["Handbook of Experimental Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2026_821","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:49:02Z","timestamp":1783705742000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/164_2026_821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":148,"URL":"https:\/\/doi.org\/10.1007\/164_2026_821","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"11 July 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}